Will IPOs Come Back? Investors Watching Anthera; Big Pharma Should Too
Executive Summary
Biotech investors are eagerly watching Anthera's proposed initial public offering for signs of life in the biotech IPO market - and biopharma business development execs should be watching carefully too
You may also be interested in...
Novartis Holds Lead In Oral MS Space With Fingolimod Filing
Novartis has gained the lead in the race to market for the first oral therapy for multiple sclerosis with the NDA submission for fingolimod, a feat made possible by FDA's refusal to file the earlier NDA for Merck Serono's oral MS candidate cladribine
Novartis Holds Lead In Oral MS Space With Fingolimod Filing
Novartis has gained the lead in the race to market for the first oral therapy for multiple sclerosis with the NDA submission for fingolimod, a feat made possible by FDA's refusal to file the earlier NDA for Merck Serono's oral MS candidate cladribine
Dealmaking When Pharma's the Only Game in Town
With no public market to provide competition, the theory among biotech's optimists was that Big Pharma would step in and buy lots of bargains. But cheap prices and easy availability haven't increased drug company appetites: They will only buy what they really want. Deal volumes, both for M&A and alliances, are falling, while Big Pharma has learned to put more of the risk back on biotech. What will change this dynamic, putting more bargaining into biotech hands, is the revival of the public market - and there are hints that such a revival may be on the way.